Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1 - Wikidata - awgldk - TriplyDB

Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1

Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q36760169

about

Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates Novel directions in HIV-1 vaccines revealed from clinical trials Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.HIV vaccine research: the challenge and the way forward Extensive recombination due to heteroduplexes generates large amounts of artificial gene fragments during PCR Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost An HIV Vaccine for South-East Asia-Opportunities and Challenges.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1 A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques.The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Natural infection as a blueprint for rational HIV vaccine design.Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection.Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C HIV-1 isolate in rhesus macaques.HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains

P2860

Q21131325-B731BDA2-2967-4E05-83AC-5E04CFDE7CB4 Q28551914-80D9767B-3756-4C2C-8B1E-F6502F7467A1 Q28552786-065EDFDC-C486-4ADD-BDCC-72CF5FFED1F8 Q33612459-083B9279-BBAF-4865-9BE6-71C5926192E8 Q33645528-42139E22-3934-457C-88CA-6294E01B1CFE Q33804531-D83548B7-4E7A-4C51-99B5-D33A7F16791C Q33939974-5546FFFE-EC40-4809-AC77-32B798E03C0B Q33977866-F262435F-DAFC-4DA5-BA36-132C96B18A50 Q34059103-C0283B7B-7B2A-48DB-83E0-FBF343890694 Q34059543-AB4FD54F-C290-47C6-8394-67E425BD98EE Q34114798-B7A56FC5-56CD-40F3-85C1-E83354C94B69 Q34133551-5987001A-E70A-41A3-BCE9-4B2284F09BCC Q34594513-ED8F9B3E-DB1F-46EE-A8E9-63C0861EF9F7 Q34721189-435B3D35-9E65-42AC-9E55-852166EED3A2 Q35061529-A160860A-833E-4AD5-88DB-B0DB048FD70F Q35076748-27DC3BA7-CD7C-47C1-8115-B7AC55ACD102 Q35227007-4EDAE262-67F5-4A3F-A677-31634CFC67B6 Q35247825-A7206A4C-8B93-456C-8004-FA3BE73B7AD9 Q35580892-80DD3D38-5125-4BF2-A661-F1D4078C4CFF Q35737800-FD1E1465-978A-4F34-BC72-C485E9BE68C6 Q35760486-69602BC2-6277-4478-BCEB-15E0A622F2F9 Q35826681-886565C7-1918-4A41-A330-03AC1E7FF719 Q35861256-41E33AD2-5030-438E-8684-07548D1D79B5 Q35861276-0E83D194-7456-4660-917C-F1741F4BF5F4 Q35894094-1E00D2D2-DFCA-48DC-A9D0-3F7A2A2C1C52 Q36080800-584C19FF-B05D-4CC4-A59E-CDD67DBA10DB Q36294739-CFE339BB-0F8C-4BE3-935E-61DA9EF10463 Q36446733-856A7364-C429-4967-8900-759067DF976F Q36702114-8A1FE880-4A16-4328-8347-0F3EA9F20BFA Q36844746-8E4C7152-3F6B-4BB2-9CE5-E92C4534EA82 Q36911772-B27E4410-A91B-4063-9A73-6CDE08FA2A09 Q37499531-96AF8272-8C53-45E4-9048-82DFAB0A179D Q37547702-E7163382-7E2A-493B-AB81-3D3336E8E4C6 Q37619134-0F95C940-80A0-4D95-8582-81646FEA5909 Q40579418-31DAE4D8-FD21-4851-99BE-D7C94E6EEFB5 Q40697873-0A80EB25-17F7-463C-83F8-0E6FC3946D8E Q40834595-FA11DE6D-37A7-4975-8502-9F1C1DC4E4D7 Q41918753-B0C41F7B-45CA-4E73-A6D5-DE7BD05687C0 Q42148035-FEF7FAEA-F755-4102-9F82-F1B1B1C2979C Q42206820-92F1D35C-5FAE-4116-8A96-A446615F59CB

P2860

Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q36760169

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@ast

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@en

type

label

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@ast

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@en

prefLabel

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@ast

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@en

P1433

Q36760169-7CE26706-E5F7-4653-9B37-D85928989189

P1476

Q36760169-7B0E67F4-8E7C-496F-BCA7-8CF99212016F

P2093

Q36760169-11389973-940A-4DE3-96DF-C561BF7B5AE0

Q36760169-205CAD8A-160F-4657-89BA-E7E9D38AA8B1

Q36760169-2F831795-D406-4DA6-B1AE-1E4B1C637B5E

Q36760169-38A8ACA2-3702-4A49-A7E5-9807EEDA995A

Q36760169-3BB4DA0B-43EB-461D-A844-D1497DE7830D

Q36760169-513132F4-C201-4FEE-BA13-82FB3A84AD1A

Q36760169-557B702A-E8EF-4C9D-8DD3-EFE35CEAA5F4

Q36760169-5A9382B1-4637-44D3-A836-F9C3BD77A0FA

Q36760169-653C636C-4BF9-4D5F-9CC2-931BE402345A

Q36760169-7C627CD5-89F4-4CDB-880D-6202DBA2BAE5

P2860

Q36760169-00D0C408-34A3-4B6A-9506-4FDE1AB27F5D

Q36760169-03AF0C0A-B336-4850-9744-2EFE80F2BBB2

Q36760169-0888EEC4-9159-4D21-BA02-D0CEF7B8169F

Q36760169-0A1C5EF0-5CF3-4B73-AA9E-4DF813EA3C7B

Q36760169-0C16F010-C10D-47DA-A0CD-6DEE9E6C693A

Q36760169-12506E1A-DB2B-464E-B65F-78930D9D204E

Q36760169-149CEE65-154E-48F3-A93E-9974A19837C2

Q36760169-1AC8D839-77F4-471D-9939-8183AEE7C981

Q36760169-24C06FD8-7B29-44FF-A0C2-3AB5BBA785AA

Q36760169-2ACCB452-52AB-4920-9A34-2CA2B2C84316

P304

Q36760169-AC8B5248-BA39-4A36-ABC4-6C83289795ED

P31

Q36760169-9E258811-F7B1-4D95-886E-10E15088C316

P356

Q36760169-18DF8C93-7D5A-4310-91DB-20DB22D10E00

P407

Q36760169-BF35C3B1-0A0C-4853-BE7A-A5E93ABA02DD

P433

Q36760169-14B301DE-E2DF-44B5-9721-281FADE9EA21

P478

Q36760169-F544EA6C-0ED8-467C-A56B-D75D9BCA5A5F

P50

Q36760169-09A21AEE-FB1A-4EE4-A304-34C08C24253F

Q36760169-71D60BC7-E59B-4153-BC40-013B15F7F74E

Q36760169-A0AC98FD-D3B5-4772-9CDC-4E58680937E4

Q36760169-A6A34EEB-6106-4901-B088-E42426511947

Q36760169-BA3A3D25-BF88-4EDB-91E7-440CF15796D5

Q36760169-CD44482C-D4EB-49A9-B38F-78E6B2044E0F

P577

Q36760169-A473B7F8-DD73-4BA6-8936-5317ECA366A7

P698

Q36760169-EB80E8C4-ED57-404E-87AD-812604199461

P932

Q36760169-F9C6DB44-C43D-4DFA-8B0E-29CD8299B760

P356

P1433

Journal of Virology

P1476

Antigenicity and immunogenicit ...... immunodeficiency virus type 1

@en

P2093

Alan Lapedes

http://www.w3.org/2001/XMLSchema#string

Andrew Foulger

http://www.w3.org/2001/XMLSchema#string

Ben-Jiang Ma

http://www.w3.org/2001/XMLSchema#string

Chun-Yen Tsao

http://www.w3.org/2001/XMLSchema#string

Cindy Bowman

http://www.w3.org/2001/XMLSchema#string

Feng Gao

http://www.w3.org/2001/XMLSchema#string

Haiyan Chen

http://www.w3.org/2001/XMLSchema#string

Hua-Xin Liao

http://www.w3.org/2001/XMLSchema#string

Julie H Blinn

http://www.w3.org/2001/XMLSchema#string

Laura L Sutherland

http://www.w3.org/2001/XMLSchema#string

P2860

Design and pre-clinical evaluation of a universal HIV-1 vaccine

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage

Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Antibody neutralization and escape by HIV-1

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

P304

4185-4201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.02297-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Beatrice H. Hahn

David C Montefiori

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23365441

http://www.w3.org/2001/XMLSchema#string

P932

3624376

http://www.w3.org/2001/XMLSchema#string